13 Oct 2023
We are pleased to share that the EMA (European Medicines Agency) has recommended the approval of Vamorolone – the first ever treatment for all patients with Duchenne. Vamorolone is an alternative to corticosteroids. It was developed with the aim of maximising...
10 Oct 2023
The World Muscle Society has once again awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena. The winner at the 28th congress in Charleston, South Carolina, USA, in October 2023 was...
1 Jul 2023
It has been a busy time in the Duchenne arena. In the US, the FDA has granted accelerated approval for the gene therapy treatment SRP-9001. This is the first time a gene therapy for Duchenne has been approved anywhere in the world, and represents a very exciting step...
22 Jun 2023
Santhera Pharmaceuticals, which manufacturers vamorolone – the steroid alternative which the DRF was involved in funding at the Phase 1 stage – has announced it has licensed vamorolone to Catalyst Pharmaceuticals in North America. Catalyst Pharmaceuticals...
28 Feb 2023
On Rare Disease Day, watch Eli Crossley, son of our friend and Duchenne UK co-founder Emily, as he talks about – and demonstrates – the amazing technological developments that are being trialled for children with Duchenne muscular dystrophy. The ‘smart...
28 Feb 2023
28th February is Rare Disease Day. Duchenne muscular dystrophy may be a rare disease, but it can bring with it challenges which are all too familiar. There is an increased risk of mental health, emotional and behavioural needs in Duchenne muscular dystrophy patients,...
3 Feb 2023
We are so proud of our co-founder, Doron Rosenfeld, who has completed his first ever marathon in 4 hours 43 minutes. Doron said: “I always promised I would never run a marathon… I never had the desire to run one, I never believed I could. But then, following...
22 Jan 2023
We are delighted that the ground-breaking KineDMD activity monitoring study we funded has been published in the prestigious scientific journal Nature Medicine. As the publication succinctly states: “Artificial intelligence has the potential to revolutionise...
7 Dec 2022
We are pleased to share that Solid Biosciences has completed its acquisition of gene therapy company AavantiBio, to create a genetic medicine company focused on neuromuscular and cardiac rare disease, with a continued, strong focus on Duchenne. At this pivotal moment...
19 Oct 2022
DMD Care UK’s new cardiac care recommendations have been published in the BMJ Open Heart journal. All Duchenne parents and caregivers are being urged to read the new guidance and share with their networks, as protecting the heart early is crucial to preventing...